The global capecitabine market is on a steady growth path, fueled by increasing cancer prevalence, growing adoption of combination therapies, and expanding access in emerging economies. The capecitabine market size was valued at USD 2.22 billion in 2024 and is projected to grow from USD 2.43 billion in 2025 to USD 4.74 billion by 2033, reflecting a...

In 2025, Medicaid has become a central point of debate in the U.S. healthcare landscape. With the Centers for Medicare & Medicaid Services (CMS) conducting stricter coverage audits, questions about Ivermectin Medicaid coverage review USA have reemerged—especially for vulnerable populations who rely on public insurance. What once seemed like a niche policy issue has now...